Categories AlphaGraphs, Earnings, Finance

PYPL Earnings Infographic: PayPal Q4 2022 profit and revenue increase

Payment solutions firm PayPal Holdings Inc. (NASDAQ: PYPL) announced financial results for the fourth quarter of 2022, reporting higher earnings and revenues.

PayPal Q4 2022 earnings infographic

Fourth-quarter revenues rose 7% year-over-year to $7.4 billion amid strong growth in payment volumes. In 2022, the company invested in the platform to better serve its customers, while focusing on and streamlining the business.

The company reported adjusted earnings of $1.24 per share for the three-month period, compared to $1.11 per share in the corresponding period of last year. On a reported basis, it was a net profit of $921 million or $0.81 per share, compared to $801 million or $0.68 per share last year.


Check this space to read management/analysts’ comments on PayPal’s Q4 2022 results


“We will continue this work throughout 2023, and I am confident that we are well-positioned to utilize our unique assets to remain a market leader in digital payments,” said PayPal’s CEO Dan Schulman.

Prior Performance

  • PayPal Q3 2022 earnings infographic

_________________________________________________________________________________________________________________

Stocks you may like:

Bank of America (BAC) Stock

Wells Fargo (WFC) Stock

JPMorgan Chase (JPM) Stock

Citigroup (C) Stock

Goldman Sachs (GS) Stock

Morgan Stanley (MS) Stock

_________________________________________________________________________________________________________________

Most Popular

Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report

Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,

J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights

The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was

Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials

Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top